Seòmar agus comataidhean

The cervical screening programme routinely invites anyone with a cervix who is between the ages of 25 and 64 for a test every 5 years. This is in line with the recommendation given by the UK National Screening Committee (UK NSC), to change the primary screening test from cytology (looking at cervical cells through a microscope to find those which could develop into cancer) to testing for high-risk human papillomavirus (HPV). The new test is more effective at identifying those at risk of developing cervical cancer, meaning those who don’t have HPV will be invited for a cervical screening test every five years instead of every three. The Scottish Government, along with the rest of the UK, is advised on all aspects of cervical screening including the move to HPV testing by the UK NSC.

Further information on the UK NSC’s recommendation can found on the following website: https://view-health-screening-recommendations.service.gov.uk/cervical-cancer/.

In Scotland, it is estimated that over 9 in 10 adults, or 93.6% of the adult community population (95% credible interval: 92.3% to 94.7%) would have tested positive for antibodies to SARS-CoV-2 from a blood sample in the week beginning 9 August 2021, suggesting that they had the infection in the past or have been vaccinated. Those who have tested positive for antibodies may have obtained them from prior infection before vaccination.

Antibody data from the ONS COVID-19 infection survey was published by the Scottish Government on 1 September 2021 at: Coronavirus (COVID-19): ONS Infection Survey – antibody data – 1 September 2021 - gov.scot (www.gov.scot).

The Scottish Government is grateful to everyone who has volunteered for COVID-19 vaccine trials in Scotland. The clinical trials participants have made an important contribution in tackling the coronavirus pandemic.

The Scottish Government are committed to ensuring that these participants are not disadvantaged. Work is ongoing to ensure that vaccine status is correctly presented on the coronavirus vaccine database.

An interim letter was sent to study investigators to send on to participants, including those in the Valneva study, on 15 July advising how they can provide vaccination status. An updated letter is currently being prepared and will be sent out in the coming weeks.

The digital application to record the COVID-19 vaccine will be available from 30 September. Clinical trial participants who have received a licenced product and are un-blinded will be able to access the application. Other clinical trial participants will not have access to the application at this time. However, other measures are in place to provide proof of vaccination.

This includes a letter of support and subsequently participants will receive a hard copy Record of Vaccination which contains security features and 1-D barcode. This Record of Vaccination can be used across the UK. In due course, this will be replaced by a QR Record of Vaccination with a QR code.

Participants should receive a record of vaccination status and do not have to do anything. If they have not received it or have lost it, they should contact their Principal Investigator.

General advice is on the NHS Inform pages at https://www.nhsinform.scot/covid-19-vaccine/after-your-vaccine/get-a-record-of-your-coronavirus-covid-19-vaccination-status and https://www.nhsinform.scot/clinicaltrialparticipants .

The UK-wide Principle Trial (Platform Randomised Trial of Treatments on the Community for Epidemic and Pandemic Illness) funded by the National Institute for Health Research (NIHR) is looking at early treatment for COVID-19 to prevent ill health and hospitalisation. It is evaluating a number of potential treatments. More information about this trial is at: Join the PRINCIPLE Trial — PRINCIPLE Trial

The Scottish Government Chief Scientist Office is also funding a trial of a potential anti-viral medicine as an early treatment of COVID-19. More information about this trial is at: GETAFIX - Glasgow Early Treatment Arm FavipiravirX (getafix-trial.org.uk)

The performance and attainment data published by The Times was obtained from the Scottish Government and is publicly available via the School Information Dashboard Profile | Tableau Public . The Scottish Government does not produce school league tables and never will. The guidance published alongside the data makes it clear that statistical data alone is not a measure of how well a school is doing. All schools are unique. To properly understand how well a school is doing it is important to look at a range of different data sources, together with information about the individual school.

A wide range of school performance and attainment data is collected and analysed by the Scottish Government to inform the National Improvement Framework and Improvement Plan for education. The information gathered identifies where further improvements can be made which will, in turn, contribute to delivering our priorities to deliver equity and excellence in Scottish education.

Information on how many people have received a dementia diagnosis in each year since 2007, broken down by NHS board, is not collected or held centrally.

Waiting times statistics for patients requiring to see a dementia specialist for a consultation or treatment are not held centrally.

The Scottish Government is supporting vital research into the immune response to COVID-19 after infection and vaccination, which is being undertaken by the SIREN (Sars-CoV-2 Immunity & Reinfection Evaluation) research study. The primary aim of the study is to determine whether the presence of antibodies to SARS-CoV-2 (anti-SARS-CoV-2) is associated with a reduction in the subsequent risk of re-infection over short term periods (reviewed monthly), the next year and in the longer-term. It will help us understand whether a previous infection of SARS-CoV-2 will offer an individual any protection against future infection of the same virus.

The Scottish Government is also participating in the recently launched Post Positive PCR Antibody Testing Initiative (PPPATI), which is using antibody testing to further our understanding of vaccine effectiveness and the immune response to COVID-19.

With the British Heart Foundation Data Science centre, the University of Edinburgh is looking at the long-term risk of deep vein thrombosis and pulmonary embolism after infection with COVID-19. Analyses are currently ongoing, but results are anticipated soon.

This work is funded by the British Heart Foundation and the Stroke Association, with support from Health Data Research UK.

The Scottish Government is not funding research specifically investigating links between long-COVID and deep vein thrombosis (DVT). However, both direct research funding and research support funding has been provided to projects that are investigating the longer term effects of COVID-19.

On December 22 2020, the Chief Scientist Office announced the outcome of its funding call for Scottish-led research on the long-term effects of COVID-19 infection. Following a competitive independently peer reviewed process 9 long-COVID research projects were funded with a total funding commitment of around £2.5 million. Details of the funded projects are available from the Chief Scientist Office website.

Long Covid Call – Chief Scientist Office (scot.nhs.uk)

It is not. The change to routine cervical screening intervals from three years to five years is due to the implementation of a test for high risk human papillomavirus (HPV) as the primary screening test in March 2020. The new test is more effective at identifying those at risk of developing cervical cancer, meaning women who don’t have HPV will be invited for a cervical screening test every five years instead of every three.